Novartis' Promacta receives FDA breakthrough designation for new indication

ZURICH (Reuters) - Novartis drug Promacta has received breakthrough therapy designation from the U.S. Food and Drug Administration for first-line treatment of severe aplastic anemia (SAA).
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news